New Zealand markets open in 2 hours 40 minutes

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0750-1.0950 (-26.29%)
As of 03:20PM EDT. Market open.

NRx Pharmaceuticals, Inc.

1201 Orange Street
Suite 600
Wilmington, DE 19801
United States
484-254-6134
https://www.nrxpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Dr. Jonathan C. Javitt M.D., M.P.H.Co-Founder, Chief Scientist Officer & Chairman873.7kN/A1957
Mr. Stephen H. Willard Esq.Acting Corporate Secretary, CEO & Director501.19kN/A1961
Dr. Riccardo Panicucci Ph.D.Chief Technology Officer240kN/A1962
Dr. Seth L. Van Voorhees Ph.D.Treasurer399.96kN/A1961
Mr. Richard Clavano NaridoInterim CFO, Principal Financial Officer & Principal Accounting OfficerN/AN/A1978
Suzanne MessereInvestor RelationsN/AN/AN/A
Dr. Philip T. Lavin Ph.D.Chief MethodologistN/AN/A1947
Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Senior ScientistN/AN/AN/A
Mr. Matthew Patrick DuffyChief Business OfficerN/AN/A1963
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.

Corporate governance

NRx Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.